Erschienen in:
01.10.2009 | Letter to the Editors
Early onset neutropenia after mycophenolate mofetil in systemic sclerosis
verfasst von:
Giovanna Cuomo, Giuseppina Abignano, Gabriele Valentini
Erschienen in:
Rheumatology International
|
Ausgabe 12/2009
Einloggen, um Zugang zu erhalten
Excerpt
Mycophenolate mofetil (MMF), by inhibiting the de novo synthesis of purines, displays potent immunosuppressive properties on B and T lymphocytes and is now widely used in transplant medicine [
1,
2] and lupus nephritis [
3,
4]. Moreover, MMF inhibits the proliferation of vascular smooth muscle cells [
5] and fibroblasts [
6], thereby suggesting that the drug might be effective in diseases such a scleroderma [
7‐
9], in which fibrotic process are prominent. …